Technology | Intravascular Imaging | May 20, 2019

Philips Launches IntraSight Interventional Applications Platform

Platform integrates intravascular imaging and physiology applications for image-guided procedures

Philips Launches IntraSight Interventional Applications Platform

May 20, 2019 — Philips announced the launch of the new IntraSight interventional applications platform. The secure, application-based platform offers a comprehensive suite of clinically proven instant wave-free ratio (iFR), fractional flow reserve (FFR), intravascular ultrasound (IVUS) and co-registration1 modalities to simplify complex interventions and speed routine procedures.

In image-guided treatments of the heart and peripheral blood vessels, there is an increasing trend to use advanced catheters and pressure wires that are capable of producing ultrasound images of the interior of blood vessels (IVUS) and perform blood pressure measurements (FFR and iFR). There is a growing body of clinical evidence that the use of such technologies in conjunction with interventional X-ray improves patient outcomes.

“IntraSight has made an immediate impact in our lab,” said Rasha Al-Lamee, M.D., clinical academic interventional cardiology consultant at Imperial College Healthcare NHS Trust, London, U.K. “It is so simple and intuitive to use that it took us no time at all to get used to it. It has made using physiology and imaging even quicker and easier, which is a great advance for us and for our patients.”

Philips IntraSight optimizes lab performance with tableside touchscreen control, systems integration, data management and remote service diagnostics. The combination of IntraSight and Azurion, Philips’ image-guided therapy platform, provides a level of diagnostic insight and intuitive tableside control that enables clinicians to provide cardiac and peripheral vascular patients with superior care. IntraSight delivers an outstanding user experience, according to Philips. with a modern, intuitive interface that minimizes learning curves and increases workflow confidence.

Further providing seamless integration in the interventional lab, Philips SyncVision, available on IntraSight 4, advances patient care by mapping both the pressure profile and IVUS measurements of the whole vessel onto the angiogram. With iFR pullback and co-registration and IVUS co-registration1, physicians can identify the precise locations causing ischemia, plan stent length and placement with a virtual stent, and predict physiologic improvement.

iFR is a pressure-derived index proprietary to Philips, allowing a simplified hyperemia-free physiological assessment of coronary blockages. It continues to be adopted into clinical practice, with mounting evidence the technology contributes to reducing costs, improving outcomes 2, 3, 4 and enhancing the patient experience.

IntraSight will be showcased at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific sessions, May 19-22 in Las Vegas, and EuroPCR, May 21-24 in Paris, France.

For more information: www.usa.philips.com/healthcare

 

References

1. Co-registration tools available within IntraSight 7 configuration via SyncVision.

2. Davies J.E., et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.

3. Gotberg M., et al. iFR Swedeheart Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.

4. Patel M. “Cost-effectiveness of Instantaneous Wave-free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision making.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018.

Related Content

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav